UNSPSC 51262202: Proroxan

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C21H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, T5WT3QN49G chemically known as 1-(1,4-benzodioxan-6-yl)-3-(3-phenyl-1-pyrrolidinyl)-1-propanone but generally known as proroxan, which bears US NIH Compound Identifier 36303. European Medicines Agency schedules Proroxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10130MIG. The term PROROXAN is an International Non-Proprietary Name or INN.

Most nations schedule proroxan under HS 29349990 and SITC 51579. As of Q4 2014, PROROXAN remains the US FDA Preferred Term for this commodity. Proroxan bears US NLM identifiers UMLS ID C0072252 and NCI Concept Code C84119. SMILES: C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4.

UNSPSC 51262202 Proroxan, a Commodity code, covers pharmaceutical products and related medical supplies procured by state and local health agencies, though recent solicitations tagged under this code show limited direct alignment with the nominal product name. Seminole County, Florida is procuring naloxone and safe drug deactivation systems through competitive bidding — 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to support community health initiatives. The Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription fulfillment programs, seeking vendor capabilities for establishing relationships outside traditional pharmacy benefit manager and group purchasing organization channels. Issuing bodies under this code include county health departments and state HHS agencies, with health and human services commissions serving as primary repeat buyers.

Activity under the code concentrates in Florida and Texas. Seminole County's naloxone and deactivation-systems IFB (Solicitation IFB60459723LAS) closed on July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; vendors were required to include all shipping and delivery costs and comply with E-Verify and drug-free workplace certifications. The Texas HHS Commission's RFI (HHS0017013) on direct-to-manufacturer prescriptions, posted April 3, 2026, served as preliminary market intelligence to inform future formal procurement strategy rather than a binding solicitation. The source shows limited geographic spread and sparse recent activity overall under this code designation — the mismatch between the code name and the actual products being solicited (naloxone and pharmacy benefit administration) suggests either miscoding in the original notices or limited relevance of the code's nominal scope to current state and local procurement activity.